COLOSTAT
LIVE

Serial Number

79220096

Owner

Vision Tech Bio Pty Ltd

Attorney

Charles G. Zug

Filing Date

Sep 20, 2017

Add to watchlist:

No watchlists yet
View on USPTO

COLOSTAT Trademark

Serial Number: 79220096 • Registration: 6044427

COLOSTAT is a trademark filed by Vision Tech Bio Pty Ltd on September 20, 2017. The trademark is classified under Class 5 (Pharmaceuticals), Class 10 (Medical Apparatus), Class 44 (Medical Services). The application is currently registered and active.

Owner Contact Info

Vision Tech Bio Pty Ltd

L17
MELBOURNE VIC 3000 , AU

Entity Type: 81

Trademark Details

Filing Date

September 20, 2017

Registration Date

May 5, 2020

Published for Opposition

March 19, 2019

Goods & Services

[ Biochemical preparations for medical and pharmaceutical use, specifically for cancer or neoplasia; ] biochemical diagnostic preparations for medical purposes; chemical diagnostic reagents for medical use; chemical diagnostic preparations for medical use [ ; diagnostic agents for pharmaceutical use being medical diagnostic reagents; ] diagnostic biomarker reagents for medical purposes; diagnostic preparations for medical use sold in kit form; diagnostic preparations for medical purposes; diagnostic reagents for medical use; diagnostic reagents for medical use sold in kit form; diagnostic substances for medical use; medical diagnostic test strips for cancer or neoplasia detection; cartridges sold prefilled with diagnostic agents for cancer or neoplasia detection; reagents for use in diagnostic tests for medical purposes; reagents for analytical purposes for medical purposes; reagents for medical use; diagnostic reagents for medical purposes; none of the foregoing being in the nature of pharmaceuticals

Medical testing and analysis for diagnostic purposes; surgical diagnostic services; providing medical information; medical services; medical treatment and medical diagnostic testing services; genetic testing services for medical purposes; medical screening services; health screening services in the field of cancer and neoplasia; medical advisory services relating to disease including providing disease risk assessment and related information

Apparatus for carrying-out diagnostic tests for medical purposes, namely, immunoassay apparatus, molecular apparatus, isoelectric focussing apparatus, SDS/PAGE apparatus, flow cytometry apparatus, mass spectrometry apparatus, MALDI-TOF apparatus, biosensor technology apparatus, evanescent fibre optic apparatus and fluorescence resonance energy transfer apparatus all for the detection of cancer or neoplasia; apparatus for diagnostic purposes, namely, medical diagnostic apparatus for detecting cancer or neoplasia; apparatus for medical diagnostic purposes, namely, immunoassay apparatus, molecular apparatus, isoelectric focussing apparatus, SDS/PAGE apparatus, flow cytometry apparatus, mass spectrometry apparatus, MALDI-TOF apparatus, biosensor technology apparatus, evanescent fibre optic apparatus and fluorescence resonance energy transfer apparatus for medical diagnostic use all for the detection of cancer or neoplasia; apparatus sold in kit form for medical diagnostic purposes, namely, diagnostic kits consisting primarily of probes, buffers and reagents for use in testing bodily fluids and bodily biological materials including blood, tissue and stool; diagnostic apparatus for medical purposes, namely, diagnostic kits consisting primarily of probes, buffers and reagents for use in liquid or tissue biopsy testing; diagnostic test kits for the detection of haemoglobin in faeces; medical apparatus for diagnostic purposes for the detection of cancer or neoplasia; medical diagnostic apparatus sold in kit form, namely, diagnostic kits consisting primarily of probes, buffers and reagents for use in testing bodily fluids and bodily biological materials, including blood, tissue and stool; medical diagnostic testing apparatus, namely, medical diagnostic testing apparatus for bodily fluids and bodily biological materials, including blood, tissue and stool; medical electronic diagnostic apparatus, namely, medical electronic diagnostic apparatus for testing bodily fluids and bodily biological materials including blood, tissue and stool; scientific apparatus for medical diagnostic purposes for testing bodily fluids and bodily biological materials including blood, tissue and stool; tools for medical diagnostics, namely, immunoassay apparatus, molecular apparatus, isoelectric focussing apparatus, SDS/PAGE apparatus, flow cytometry apparatus, mass spectrometry apparatus, MALDI-TOF apparatus, biosensor technology apparatus, evanescent fibre optic apparatus and fluorescence resonance energy transfer apparatus for testing bodily fluids and bodily biological materials including blood, tissue and stool; medical apparatus instruments, namely, namely, immunoassay apparatus, molecular apparatus, isoelectric focussing apparatus, SDS/PAGE apparatus, flow cytometry apparatus, mass spectrometry apparatus, MALDI-TOF apparatus, biosensor technology apparatus, evanescent fibre optic apparatus and fluorescence resonance energy transfer apparatus for testing bodily fluids and bodily biological materials including blood, tissue and stool; in vitro diagnostic testing apparatus for medical use for the detection of cancer or neoplasia

Filing History

COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
May 5, 2025 REM3
INVALIDATION REVIEWED - NO ACTION REQUIRED BY OFFICE
Apr 26, 2022 INNA
PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED
Dec 11, 2021 INPR
LIMITATION FROM THE IB EXAMINED AND ENTERED
Apr 12, 2021 LIME
CORRECTION UNDER SECTION 7 - PROCESSED
Apr 11, 2021 COC.
ASSIGNED TO PARALEGAL
Apr 11, 2021 PLGL
LIMITATION OF GOODS RECEIVED FROM IB
Feb 28, 2021 LIMG
FINAL DECISION TRANSACTION PROCESSED BY IB
Oct 3, 2020 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Sep 11, 2020 FICS
FINAL DISPOSITION PROCESSED
Sep 11, 2020 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Aug 5, 2020 FICR
REGISTERED-PRINCIPAL REGISTER
May 5, 2020 R.PR
TTAB RELEASE CASE TO TRADEMARKS
Apr 1, 2020 TMBN
OPPOSITION TERMINATED NO. 999999
Apr 1, 2020 OP.T
OPPOSITION DISMISSED NO. 999999
Apr 1, 2020 OP.D
REFUSAL PROCESSED BY IB
May 10, 2019 RFNP
OPPOSITION INSTITUTED NO. 999999
Apr 24, 2019 OP.I
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Apr 19, 2019 OPNX
OPPOSITION NOTICE (IB REFUSAL) SENT TO IB
Apr 17, 2019 OPNS
OPPOSITION NOTICE (IB REFUSAL) CREATED
Apr 17, 2019 OPNC
OPPOSITION PAPERS RECEIVED AT TTAB
Apr 16, 2019 OPPF
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Apr 3, 2019 OPNS
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Apr 3, 2019 OPNR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Mar 19, 2019 NPUB
PUBLISHED FOR OPPOSITION
Mar 19, 2019 PUBO
NOTIFICATION PROCESSED BY IB
Mar 15, 2019 GPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Feb 27, 2019 OPNS
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Feb 27, 2019 NONP
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Feb 27, 2019 OP2R
LAW OFFICE PUBLICATION REVIEW COMPLETED
Feb 14, 2019 PREV
ASSIGNED TO LIE
Feb 11, 2019 ALIE
APPROVED FOR PUB - PRINCIPAL REGISTER
Jan 28, 2019 CNSA
EXAMINER'S AMENDMENT ENTERED
Jan 23, 2019 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Jan 23, 2019 GNEN
EXAMINERS AMENDMENT E-MAILED
Jan 23, 2019 GNEA
EXAMINERS AMENDMENT -WRITTEN
Jan 23, 2019 CNEA
LIMITATION FROM THE IB - REQUEST EXAM REVIEW
Dec 7, 2018 LIME
LIMITATION OF GOODS RECEIVED FROM IB
Nov 2, 2018 LIMG
NOTIFICATION OF FINAL REFUSAL EMAILED
Aug 4, 2018 GNFN
FINAL REFUSAL E-MAILED
Aug 4, 2018 GNFR
FINAL REFUSAL WRITTEN
Aug 4, 2018 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Jun 29, 2018 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jun 28, 2018 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jun 28, 2018 TROA
REFUSAL PROCESSED BY IB
Feb 3, 2018 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Jan 13, 2018 RFCS
REFUSAL PROCESSED BY MPU
Jan 13, 2018 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Dec 30, 2017 RFCR
NON-FINAL ACTION WRITTEN
Dec 29, 2017 CNRT
ASSIGNED TO EXAMINER
Dec 25, 2017 DOCK
APPLICATION FILING RECEIPT MAILED
Nov 11, 2017 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Nov 7, 2017 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Nov 2, 2017 REPR